Cancer Vaccine
CD1d-restricted T cells license B cells to generate cytotoxic antitumor immunity
Published in Drug Week, September 8th, 2006
"Although resting B cells are known for being poorly immunogenic and for inducing T-cell tolerance, we have attempted to test whether their immunogenicity could be enhanced by CD1d-restricted invariant T cells (iNKT) to a point where they could be used in cellular vaccines," scientists in South Korea report.
"We found that the addition of the iNKT ligand alpha-galactosylceramide (alpha GalCer) to peptide-loaded B cells overcame peptide-specific T-cell unresponsiveness and allowed for the generation of peptide-specific memory CTL immunity," said...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
Source: Drug Week (2006-09-08)
More Articles from Drug Week
- Drug Delivery
Low temperature sensitive liposome-doxorubicin may improve drug delivery to solid tumors - Drug Development
Human primary renal cells used as model for toxicity assessment of chemotherapeutic drugs - Osteoarthritis
IDEA reports positive phase III results for targeted analgesic IDEA-033 - Pharmacokinetics
Interactions between simvastatin and omega-3-acid ethyl esters were examined - Systemic Lupus Erythematosus
Human Genome Sciences launches phase III clinical development program for LymphoStat-B - Acute Myeloid Leukemia
Dacogen (decitabine) for Injection receives U.S. orphan drug designation for patients with AML - More from this issue of Drug Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
